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Background: Inherited neurotransmitter disorders are primary defects of neurotransmitter metabolism. The main
purpose of this retrospective cohort study was to identify prevalence of inherited neurotransmitter disorders.
Methods: This retrospective cohort study does not have inclusion criteria; rather included all patients who
underwent cerebrospinal fluid (CSF) homovanillic and 5-hydroxyindol acetic acid measurements. Patients with CSF
neurotransmitter investigations suggestive of an inherited neurotransmitter disorder and patients with normal or
non-diagnostic CSF neurotransmitter investigations underwent direct sequencing of single gene disorders.
Results: There were 154 patients between October 2004 and July 2013. Four patients were excluded due to
their diagnosis prior to this study dates. Two major clinical feature categories of patients who underwent lumbar
puncture were movement disorders or epilepsy in our institution. Twenty out of the 150 patients (13.3%) were
diagnosed with a genetic disorder including inherited neurotransmitter disorders (6 patients) (dihydropteridine
reductase, 6-pyruvoyl-tetrahydropterin synthase, guanosine triphosphate cyclohydrolase I, tyrosine hydroxylase,
pyridoxine dependent epilepsy due to mutations in the ALDH7A1 gene and pyridoxamine-5-phosphate oxidase
deficiencies) and non-neurotransmitter disorders (14 patients).
Conclusion: Prevalence of inherited neurotransmitter disorders was 4% in our retrospective cohort study. Eight
out of the 150 patients (5.3%) had one of the treatable inherited metabolic disorders with favorable short-term
neurodevelopmental outcomes, highlighting the importance of an early and specific diagnosis. Whole exome or
genome sequencing might shed light to unravel underlying genetic defects of new inherited neurotransmitter
disorders in near future.
Keywords: Inherited neurotransmitter disorders, Genetics, Movement disorders, Monoamine metabolism, Pyridoxine
metabolism, EpilepsyBackground
Inherited neurotransmitter disorders are primary defects
of neurotransmitter metabolism and transport. They
include defects of catecholamine, serotonin, biopterin,
glycine, pyridoxine and gamma amino butyric acid (GABA)
metabolism [1,2]. Defects of catecholamine (dopamine,* Correspondence: saadet.mahmutoglu@sickkids.ca
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article, unless otherwise stated.epinephrine and norepinephrine) and serotonin metabolism,
also called monoamine or biogenic amine metabolism,
are the most widely known and investigated group of
neurotransmitter disorders [3-7]. Two cofactors are
required for the synthesis of dopamine and serotonin:
tetrahydrobiopterin and pyridoxal 5′-phosphate [4,5]. The
end products of dopamine, serotonin, and norepinephrine
within the central nervous system (CNS) are homovanillic
acid (HVA), 5-hydroxyindolacetic acid (5-HIAA) and
3-methoxy 4-hydroxypenylglycol (MHPG), respectively
(Figure 1). The cerebrospinal fluid (CSF) diagnosticBioMed Central. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 The monoamine neurotransmitter pathway. Abbreviations: GTP=guanosine triphosphate; GTPCH=guanosine triphosphate cyclohydrolase 1;
PTPS = 6-pyruvoyltetrahydropterin synthase; SR= sepiapterin reductase; BH4= tetrahydrobiopterin; TH= tyrosine hydroxylase; DHPR=dihydropteridine reductase;
qBH2=quinonoid dihydrobiopterin; 5-HTP=5-hydroxytryptophan; L-dopa= levodihydroxyphenylalanine; PLP=pyridoxal phosphate; AADC= aromatic L-amino
acid decarboxylase; 5-HIAA=5-hydroxyindoleacetic acid; HVA=homovanillic acid; MHPG=3-methoxy-4-hydroxylphenylglycol; VMA=vanillylmandelic acid.
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biopterin metabolism are tetrahydrobiopterin, biopterin,
and neopterin [8].
Tyrosine hydroxylase (TH) deficiency affects the syn-
thesis of dopamine, epinephrine and norepinephrine,
whereas aromatic L-amino acid decarboxylase (AADC)
and tetrahydrobiopterin metabolism defects including
guanosine triphosphate cyclohydrolase I (GTPCH), dihy-
dropteridine reductase (DHPR), 6-pyruvoyltetrahydropterin
synthase (PTPS), sepiapterin reductase (SR) deficiencies
lead to a deficiency of serotonin in addition to deficiencies
of dopamine, epinephrine and norepinephrine [1-5].
Lumbar punctures are widely used among patients
with neurological signs and symptoms such as seizures,
developmental delay, central hypotonia, and movement
disorders including chorea, choreoathetosis, dystonia,
dyskinesia, and ataxia [9-14]. The GTPCH, PTPS, DHPR
and SR deficiencies are treatable. In patients with severe
phenotype of AADC and TH deficiencies, treatments
alleviate symptoms but do not affect neurodevelopmental
disabilities. As the majority of inherited neurotransmitter
disorders are treatable, CSF neurotransmitter measurements
would be necessary to diagnose these disorders for
the initiation of the disease specific treatment.There are no incidence studies for inherited neurotrans-
mitter disorders in the general population. It is also un-
known if these disorders are under-diagnosed due to the
nonspecific constellation of symptoms, as well as the cum-
bersome collection of CSF samples and lack of availability of
metabolite measurements in laboratories in North America
and Europe.
We performed a retrospective cohort study to investigate
the diagnostic yield and the prevalence of inherited
neurotransmitter disorders in patients who underwent
lumbar puncture for the measurement of CSF HVA
and 5-HIAA at The Hospital for Sick Children.
Methods
This retrospective cohort study was approved by
Institutional Research Ethics Board (REB #1000032023). All
patients originating from The Hospital for Sick Children,
Toronto, Canada were included who had the measurement
of CSF HVA and 5-HIAA in the Medical Neurogenetic
Laboratory in Atlanta. This laboratory is the reference
clinical laboratory for the CSF neurotransmitter measure-
ments for our hospital. Their database was searched using
The Hospital for Sick Children to identify patient names
for this retrospective cohort study. As we have no database
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CSF neurotransmitter measurements in our institution, this
was the only way to develop patient cohort for this retro-
spective study. For these reasons, this study does not have
inclusion criteria; rather included all patients originating
from The Hospital for Sick Children who underwent CSF
neurotransmitter measurements in a single laboratory for
the diagnostic work-up. The main purpose of this
retrospective cohort study was to identify prevalence
of inherited neurotransmitter disorders.
The demographic, clinical, biochemical, molecular genetics
and neuroimaging features were reviewed from electronic
patient charts for all patients. Briefly, CSF samples were col-
lected into pre-prepared tubes numbered from 1 to 5 ac-
cording to reference clinical laboratory’s sample collection
requirements. Dithioerythritol and diethylenetriaminepenta-
acetic acid were added to the tube #3 to prevent the oxida-
tion of tetrahydrobiopterin [15]. Samples were placed on ice
and transferred immediately into the laboratory for freezing
at −80°C until measurements. CSF samples contaminated
with blood due to traumatic sample collection were centri-
fuged in cold centrifuge immediately and clear CSF sample
was transferred into new tubes as described previously [3].
All samples were shipped to Medical Neurogenetics
Laboratory in Atlanta on dry ice for the CSF neurotrans-
mitter measurements. HVA, 5-HIAA and 3-OMD levels
were measured in the first 0.5 mL of CSF sample. If HVA
and 5-HIAA levels were abnormal, tetrahydrobiopterin
and neopterin levels were measured in the third sample.
Measurements were obtained using high-performance
liquid chromatography with a combination of electro-
chemical and fluorescence detectors [3]. Metabolite levels
were compared against age-appropriate reference ranges.
CSF glucose and CSF 5- methylenetetrahydrofolate levels
were also measured in some of the patients.
Patients with positive newborn screening for phenylke-
tonuria (PKU) underwent sapropterin loading test, urine
pterin metabolites and measurement of DHPR enzyme
activity on dried blood spots in the neonatal period.
Patients with normal or non-diagnostic CSF neurotrans-
mitter metabolite measurements underwent direct se-
quencing of genes based on clinical (including paroxysmal
events, hereditary spastic paraplegia, epilepsy, severe
hypotonia or positive family history) or biochemical fea-
tures (including elevated homocysteine, low CSF glucose,
low CSF 5-methylenetetrahydrofolate levels) suggestive of
single gene disorders or targeted next-generation sequen-
cing for epileptic encephalopathy gene panel in various
clinical molecular genetics laboratories.
All information was entered into an Excel database for
analysis. The Alamut database, Exome database Variant
Server (http://evs.gs.washington.edu/EVS/), and dbSNP
database (http://www.ncbi.nlm.nih.gov/projects/SNP/)
were used for the annotation of novel genetic variants.Pathogenicity of missense variants were assessed by
cross-species conservation of nucleotides and amino
acid sequences using gene and protein sequences
from the Alamut database. In silico splice tools were
used to test the potential effects of new synonymous or
intronic variations on premRNA splicing. We used the
recommendations for mutation nomenclature (www.hgvs.
org/mutnomen) to name gene variations.
Results
154 patients underwent lumbar puncture for CSF HVA
and 5-HIAA at The Hospital for Sick Children between
October 2004 and July 2013. Four patients were excluded
because they had diagnosis of DHPR deficiency and
underwent CSF HVA and 5-HIAA measurements for the
guidance of the treatment during this retrospective cohort
study period. The remaining 150 patients were included in
this study. Two major clinical feature categories of
patients who underwent lumbar puncture were movement
disorders or epilepsy in our institution. There was no
diagnosis in 130 patients and there was a confirmed
underlying genetic diagnosis in 20 patients (Figure 2).
Patients with a confirmed genetic diagnosis were divided
into 2 groups: 1) Inherited neurotransmitter disorders
including catecholamine, serotonin, tetrahydrobiopterin
and pyridoxine metabolism disorders (6 patients, 4%); 2)
Non-neurotransmitter disorders with a confirmed under-
lying genetic diagnosis (14 patients, 9.3%).
The demographics, clinical features and their distribution
and the number of the patients with a confirmed diagnosis
for neurotransmitter and non-neurotransmitter disorders
are listed in Tables 1 and 2 respectively.
Inherited neurotransmitter disorders
There were 6 patients from 6 unrelated families in
this group. Their clinical, biochemical, neuroimaging,
molecular genetic investigations, and treatment outcome
are summarized in Table 3.
In this group, 2 patients (33%) were identified by positive
newborn screening for PKU: one had PTPS deficiency and
another one had DHPR deficiency in the neonatal period
based on the response to sapropterin loading test, or non-
detectable DHPR enzyme activity on dried blood spots or
elevated urine neopterin and neopterin to biopterin ratio.
In 3 out of 6 patients (50%), the diagnosis was suspected
based on the abnormal CSF HVA and/or 5-HIAA
levels leading to diagnosis of the following inherited
neurotransmitter disorders including autosomal dominant
GTPCH deficiency, TH deficiency, pyridoxine dependent
epilepsy (PDE) caused by mutations in the ALDH7A1 gene
(PDE-ALDH7A1) (Table 2). In one patient with PNPO
deficiency (10%), mildly elevated CSF threonine and
3-OMD levels as well as response to pyridoxal-5-phosphate
therapy led the confirmation of the diagnosis [19]. Two
Figure 2 Distribution of 154 study patients with or without genetic diagnosis.
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patient with ataxia and tremor; one patient with dystonia
and choreoathetosis), and two patients (33%) presented
with GDD and epilepsy.
We identified 6 variants (2 novel and 4 known) in 6
genes including QDPR, PTS, GCH1, TH, ALDH7A1 and
PNPO genes in 6 patients. Five patients (83%) were
homozygous for the variants (Table 3). In all patients
with autosomal recessive disorder, carrier status was
confirmed in both parents. None of the novel variantsTable 1 Demographics and clinical features of the patients w
non-neurotransmitter disorders
Demographics of the patients Inherited neurotransmitte
Number of patients 6
Average age of onset (range) 3.8 ± 6.0 SD months (1 day
Average age of diagnosis (range) 26.5 ± 42.6 SD months (1 to
Current average age (range) 5.8 ± 4.4 SD years (1 to 14 y
Inheritance pattern AR (5 patients, 83%) AD (1 p
Clinical features
Newborn screening positive for PKU 2 patients (33%)
Movement disorder and/or GDD 2 patients (33%)
GDD and/or epilepsy 2 patients (33%)
Neonatal hypotonia None (0%)
Abbreviations: SD standard deviation, AR autosomal recessive, AD autosomal dominawere found in either ESP6500 Exome or dbSNP database
as polymorphisms. The variants were highly conserved
across all species and reported to be deleterious in SIFT
and/or Mutation Taster prediction programs, and all
were likely disease causing mutations. Missense muta-
tions, small deletion/insertions and splice site variants
were equally occurred (Table 3).
In this group, 5 patients (83%) had a treatable inherited
neurotransmitter disorders including GTPCH deficiency,
PTPS deficiency, DHPR deficiency, PDE-ALDH7A1 andith inherited neurotransmitter disorders and
r disorders Non-neurotransmitter disorders
14
to 17 months) 10.5 ± 16.2 SD months (1 day to 60 months)
120 months) 75.3 ± 64.8 SD months (7 to 216 months)
ears) 10.3 ± 6.4 SD years (3 to 19 years)
atient, 17%) AR (6 patients, 43%) AD (5 patients, 36%) X-linked





nt, GDD global developmental delay.
Table 2 Clinical features and diagnostic yield of the patients who underwent CSF neurotransmitter measurements
including the inherited neurotransmitter and non-neurotransmitter disorders
Category of clinical features Patient number
(percent)
Patient number for inherited
neurotransmitter disorders
Patient number for non-neurotransmitter
disorders
Movement disorder and/or GDD 38 (25%) 2 patients 1 patient
GDD and movement disorder and epilepsy 18 (12%) None 4 patients
GDD and epilepsy 66 (44%) 2 patients 7 patients
GDD and hypotonia 26 (17.5%) None 2 patients
Newborn screening positive for PKU 2 (1.5%) 2 patients None
Abbreviations: GDD global developmental delay, PKU phenylketonuria.
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tions from the newborn period, the patient with DHPR
deficiency had severe global developmental delay and
cognitive dysfunction at the age of 9 years due to
non-adherence to diet and medication treatment by
parents. The treatment improved choreoathetoic move-
ment disorder in the very severe TH deficiency patient, but
did not change the severity of neurocognitive dysfunction








1/M/9 yr/DHPR def NBS-Pos-PKU/7 d/<15 d ↓123/↓55/↑2441/
↓14 (3.5 yr) on treat
2/F/3 yr/PTPS def NBS-Pos-PKU/6 d/12 d ↓157/↓78/NP/↓
< 5/ ↑123 N (12 d)
3/F/14 yr/GTPCH def GM delay, ataxia,
tremor/17 mo/10 yr
↓121/N/N/↓8/↓
< 5 (13 yr)
4/F/3 yr/TH def GDD, choreoathetosis,
dystonia/2 mo/24 mo
↓7/N/N (2 yr)
5/F/5 yr/PDE-ALDH7A1 Seizures, GDD/3.5
mo/11 mo
↓175/↓110/N (7 mo)




Abbreviations: CSF cerebral spinal fluids, HVA homovanillic acid, 5-HIAA 5-hydroxyind
THB tetrahydrobiopterin, Neo neopterin, DHPR dihydropterine reductase, def deficie
phenylketonuria, d day(s), mo month(s), GDD global developmental delay, NP not p
PKU phenylketonuria, PTPS 6-pyruvoyl-tetrahydropterin synthase, GTPCH guanosine trip
PDE-ALDH7A1 pyridoxine dependent epilepsy caused by mutations in the ALDH7A1 ge
GTS generalized tonic seizures, PLP pyridoxal-5-phosphate, yr year(s), GTCS generalized
3: ; ↑ = elevated; ↓ = decreased.
*Age appropriate reference ranges for CSF neurotransmitters and amino acids: CSF
0.5 – 2 years = 294 – 1115 nmol/L; 2 – 5 years = 233–928 nmol/L; 5 – 10 years = 218
CSF 5HIAA: 0–0.2 years = 208 – 1159 nmol/L; 0.2 - 0.5 years = 179 – 711 nmol/L; 0.5
66 – 338 nmol/L; 10 – 15 years = 67 – 189; adults = 67–140 nmol/L.
CSF 3-O-MD: 0–0.2 years = <300 nmol/L; 0.2 - 0.5 years = <300 nmol/L; 0.5 – 2 years
10 – 15 years = <100 nmol/L; adults = <100 nmol/L.
CSF tetrahydrobiopterin: 0–0.2 years = 40–105 nmol/L; 0.2-0.5 years = 23–98 nmol/L;
years = 9–32 nmol/L; adults = 10–30 nmol/L.
CSF neopterin: 0–0.2 years = 7–65 nmol/L; 0.2-0.5 years = 7–65 nmol/L; 0.5-2 years =
10–15 years = 8–33 nmol/L; adults = 8–28 nmol/L.
CSF threonine: 28–92 μmol/L.Additionally, 4 patients with a genetically confirmed
diagnosis of DHPR deficiency who were diagnosed
prior to October 2004 were reviewed for long-term
treatment outcome, but not included into the prevalence
calculations. A 15-year-old female with therapeutic phenyl-
alanine levels by protein restricted diet and excellent
compliance to l-dopa/carbidopa, 5-hydroxytryptophan
and folinic acid treatments had normal neurocognitive




Homozygous novel IVS5+ 1
G > T in QDPR gene
L-dopa/carbidopa 9 mg/kg/d,
5-HTP 7.5 mg/kg/d/severe GDD
Homozygous known [16]
c.200C > T (p.Thr67Met) in
PTS gene
L-dopa/carbidopa 7.13 mg/kg/d,














IVS-12(+1) G > A in
ALDH7A1 gene





PLP 35 mg/k/d/seizure free,
normal development
ol acetic acid, 3-OMD 3-O-methyldopa, LP lumbar puncture,
ncy, GA-I glutaric aciduria type I, NBS-Pos-PKU newborn screening positive for
erformed, ProReD protein restricted diet, 5-HTP 5-hydroxytryptophane,
hosphate cyclohydrolase, GM gross motor, TH tyrosine hydroxylase,
ne, PNPO pyridox(am)ine-5-phosphate oxidase, MS myoclonic seizures,
tonic-clonic seizures.
HVA: 0–0.2 years = 337–1299 nmol/L; 0.2 - 0.5 years = 450–1132 nmol/L;
–852 nmol/L; 10 – 15 years = 167–563 nmol/L; adults = 145–324 nmol/L.
- 2 years = 129 – 520 nmol/L; 2 – 5 years = 74 – 345 nmol/L; 5 – 10 years =
= <300 nmol/L; 2 – 5 years = <150 nmol/L; 5 – 10 years = <100 nmol/L;
0.5-2 years = 18–58 nmol/L; 5–10 years = 9–40 nmol/L; 10–15
7–65 nmol/L; 2–5 years = 7–65 nmol/L; 5–10 years = 7–40 nmol/L;
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cations, and demonstrated mild to severe neurocognitive
dysfunction.
Non-neurotransmitter disorders with a confirmed
underlying genetic diagnosis
In this group, a genetic diagnosis was confirmed in 14
patients (9.3%). Patients with normal or non-diagnostic
CSF neurotransmitter results underwent targeted single
gene testing based on their clinical features. Lumbar
puncture guided the diagnosis of glucose transporter 1
(GLUT1) deficiency in one patient with low CSF glucose
level and severe methylenetetrahydrofolate reductase
(MTHFR) deficiency in another patient with low CSFTable 4 Patients with non-neurotransmitter disorders with a
Patients/sex/current age/
diagnosis








2/F/3 yr/cobolamin G def. GDD, epilepsy/2 mo/7 mo ↓2
28
3/M/11 yr GLUT1 def. GDD, epilepsy, 2 yr/11 yr N
4/F/16 yr/calcium
channelopathy
GDD, epilepsy, ataxia, t
remor/15 mo/10 yr
↓1






epilepsy/ 1.5 yr/12 yr
N













10/F/4 yr/KCNQ2 EE GDD, epilepsy/1 wk/4.5 yr N
11/ F/3 yr/STXBP1 EE GDD, epilepsy/birth/4 yr N





GDD, epilepsy/birth/1 yr N
14/M/passed away (2 mo)/
asparagine synthetase def.
GDD, hypotonia/2 mo ↓2
Abbreviations: CSF cerebral spinal fluids, HVA homovanillic acid, 5-HIAA 5-hydroxyind
def. deficiency, MTHF methylenetetrahydrofolate, d day(s), mo month(s), yr year(s), G
transporter 1. 3: ; ↑ = elevated; ↓ = decreased.
*Age appropriate reference ranges for CSF neurotransmitters, amino acids and glucose
– 2 years = 294 – 1115 nmol/L; 2 – 5 years = 233–928 nmol/L; 5 – 10 years = 218–852 n
CSF 5HIAA: 0–0.2 years = 208 – 1159 nmol/L; 0.2 - 0.5 years = 179 – 711 nmol/L; 0.5
years = 66 – 338 nmol/L; 10 – 15 years = 67 – 189; adults = 67–140 nmol/L.
CSF 3-O-MD: 0–0.2 years = <300 nmol/L; 0.2 - 0.5 years = <300 nmol/L; 0.5 – 2 years
10 – 15 years = <100 nmol/L; adults = <100 nmol/L.
CSF MTHF: 40–120 nmol/L all age groups.
CSF glucose: 2.1-3.6 mmol/L.5-MTHF level. Three out of 14 patients (21%) had one of
the treatable inherited metabolic disorders including co-
balamin G, MTHFR and GLUT1 deficiencies. Clinical,
biochemical, molecular genetic results of these patients
are summarized in Table 4.
In all patients with autosomal recessive disorder,
carrier status was confirmed in both parents. In all patients
with autosomal dominant disorder, variants occurred de
novo. None of the novel variants were found in either
ESP6500 Exome or dbSNP database as polymorphisms.
The variants were highly conserved across all species and
reported to be deleterious in SIFT and/or Mutation Taster
prediction programs, and all were likely disease causing
mutations.confirmed inherited metabolic or genetic disease
F* HVA/5-HIAA/3-OMD/








Homozygous known [20] c.340_166A
> G in MTR gene
/N/N/glucose 2.1 (8 yr) Heterozygous, de novo, known [21] c.823G >
A (p.Ala275Thr) in SLC2A1 gene
23/N/N (10 yr) Heterozygous, de novo, novel c.2134A > G
(p.Ile712Val) in CACNA1A gene
/N/N (2 yr) Heterozygous, de novo, novel c.4046G >
A (p.Arg1349Glu) in CACNA1A gene
/↓50/N (7 yr) Homozygous 0.132 MB deletion at 9p21.1
in aCGH loss of both copies of APTX gene
/N/N (16 yr) Heterozygous known [22,23] c.3664_3665insT
novel r.4667_4774del (36 AA del) in SPG11
gene (RT-PCR)
45/N/N (7 yr) Heterozygous novel c.869C > T (p.Ser290Phe)
in SLC16A2 gene
/N/N (2 wk) Abnormal methylation of SNRPN gene
/N/N (1 mo) Heterozygous, de novo, novel c.700A > C
(p.Thr234Pro) in KCNQ2 gene
/N/N (3mo) Heterozygous, de novo, novel c.364C > T
(p.Arg122X) in STXBP1 gene
/N/N (1mo) Homozygous known [24] c.1274C > T
(p.Tyr425Met) in SLC6A5 gene
/N/N (7mo) Novel 20q13.33 1.2 Mb deletion on aCGH
40/ ↓183/N (2mo) Homozygous known [25] c.1648C > T;
(p.Arg550Cys) in ASNS gene
ol acetic acid, 3-OMD 3-O-methyldopa, LP lumbar puncture,
DD global developmental delay, N normal, GLUT1 glucose
: CSF HVA: 0–0.2 years = 337–1299 nmol/L; 0.2 - 0.5 years = 450–1132 nmol/L; 0.5
mol/L; 10 – 15 years = 167–563 nmol/L; adults = 145–324 nmol/L.
- 2 years = 129 – 520 nmol/L; 2 – 5 years = 74 – 345 nmol/L; 5 – 10
= <300 nmol/L; 2 – 5 years = <150 nmol/L; 5 – 10 years = <100 nmol/L;
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Our retrospective cohort study reports 4% prevalence of
inherited neurotransmitter disorders in patients with
GDD, neonatal hypotonia, neonatal seizures, epilepsy
and movement disorders, who underwent measurements
of CSF catecholamine and serotonin metabolites for diag-
nostic work-up in a single center. Autosomal dominant
GTPCH deficiency, TH deficiency, PTPS deficiency,
DHPR deficiency, PDE-ALDH7A1 and PNPO deficiency
combining inherited monoamine and pyridoxine metabol-
ism disorders were identified in our study cohort. The
prevalence of inherited monoamine metabolism disorders
(autosomal dominant GTPCH, TH, DHPR and PTPS
deficiencies) was 1.3% (4 out of 150 patients), which is
similar compared to a previous study reporting 1.5%
prevalence [26]. In a retrospective study of 62 patients who
underwent CSF metabolic investigations for neurometa-
bolic disorders, 16 patients (25.8%) were biochemically
diagnosed with inherited neurotransmitter disorders [13].
None of these diagnoses were confirmed by molecular
genetic investigations and the study included serine biosyn-
thesis defects and cerebral folate deficiency, which are not
classified as inherited neurotransmitter disorders [1]. For
these reasons, this high prevalence of 25.8% is not a true
prevalence study [13]. In our retrospective cohort study,
9.3% (14 out of 150) of the patients with normal or non-
diagnostic CSF catecholamine and serotonin metabolite
measurements had an identifiable genetic cause other
than inherited neurotransmitter disorders (Figure 1). Ap-
proximately 5.3% (8 out of 150) of the patients had one of
the treatable inherited neurotransmitter disorder or inher-
ited metabolic disorder with favorable short-term neuro-
developmental outcomes, highlighting the importance of
an early and specific diagnosis. This is a retrospective co-
hort study and does not include all patients who under-
went lumbar puncture during the study period in our
hospital. It might be likely that other neurotransmitter
disorders, such as glycine encephalopathy and GABA me-
tabolism disorders, are not captured, which might be diag-
nosed during this retrospective cohort study period.
The estimated incidence of inherited monoamine
metabolism disorders with hyperphenylalaninemia is
1-2% of all patients with a positive screen for PKU in
the newborn screening programs [7]. In our province,
about 150,000 newborns per year are screened and
our hospital is the reference center for about 50% of
newborns. In our study, the estimated incidence of
PTPS or DHPR deficiencies was about 1:320,000 newborns
for each PTPS and DHPR deficiencies. In a recent large
international registry of patients with tetrahydrobiopterin
metabolism defects (BIODEF; http://www.biopku.org), PTPS
deficiency was the most common disorder (56.7%) and
DHPR deficiency was the second most common disorder
(34.7%) [7]. There are no detailed long-term treatmentoutcome studies reporting whether DHPR deficiency re-
sults in normal neurocognitive outcome. In our small study
cohort, there were 5 patients with DHPR deficiency and
long-term treatment outcome was available in four patients.
One of the patients with strict phenylalanine-restricted diet
and l-dopa/carbidopa and 5-hydroxytryptophan treatment
had normal neurocognitive outcome at the age of 13 years,
whereas, 3 patients with treatment compliance problems
had various degrees of neurocognitive dysfunction. Detailed
retrospective treatment outcome studies of patients with
DHPR deficiency would be necessary to increase our
understanding for this treatable disease. Studies are
underway to determine, if sapropterin would be help-
ful to control phenylalanine levels instead of protein
restricted diet to decrease further burden to the families
as well as to decrease contribution of additional high
phenylalanine neurotoxicity.
Autosomal dominant GTPCH deficiency is one of the
rare and treatable inherited monoamine metabolism
disorders [27]. Patients usually present with dystonia
in childhood. Atypical presentations with Parkinsonian
features e.g. tremor, have also been reported. In a review
article, all patients had low CSF HVA, neopterin, and biop-
terin levels, and some patients had low to low-normal CSF
5-HIAA levels [27-29]. Our patient presented with tremors
at the age of ten years, leading to measurements of CSF
neurotransmitter metabolites and the diagnosis of
autosomal dominant GTPCH deficiency. Less than 80
patients have been reported since the first description
of TH deficiency. According to the recent phenotypic
classification [30], our patient had very severe phenotype
and was on high dose of L-dopa/carbidopa treatment.
The only benefit of this treatment is improvements
in choreoathetosis, which is in line with the patients
reported in the literature for very severe phenotype
of TH deficiency.
Low HVA levels secondary to various neurological
disorders have been reported between 6-20% of patients
[26,31]. In those studies, between 20-37% of the patients
were diagnosed with one of the non-neurotransmitter
genetic disorders [26,31]. In our cohort, 8 out of the 150
patients (5.3%) had low HVA and 5 (62.5%) of these
patients had an underlying inherited neurotransmitter or
non-neurotransmitter disorder with a confirmed under-
lying genetic diagnosis. In our retrospective cohort study,
abnormal CSF neurotransmitter metabolite levels were
present in 10 out of 130 (7.7%) patients with no identifi-
able genetic cause and 6 patients (60%) presented with a
movement disorder including ataxia, tremor or dystonia.
Interestingly, one of the patients was diagnosed with
pyridoxal-phosphate responsive epilepsy based on the low
HVA, 5-HIAA and pyridoxal-5-phosphate levels in CSF
and responded to pyridoxal-5-phosphate monotherapy
with seizure freedom. In this patient PDE-ALDH7A1 and
Mercimek-Mahmutoglu et al. Orphanet Journal of Rare Diseases  (2015) 10:12 Page 8 of 9PNPO deficiency have been excluded based on the normal
urine alpha-amino adipic semialdehyde, direct sequencing
and multiplex ligation dependent probe amplification of
the ALDH7A1 and PNPO genes.
Targeted next-generation sequencing for movement dis-
orders utilizing 151-gene panel has been recently reported
with a diagnostic yield of 20% compared to targeted single
gene Sanger sequencing diagnostic yield of 5% [32]. Tar-
geted next-generation sequencing for epilepsy utilizing 35-
265-gene panels has been previously reported with diag-
nostic yields ranging between 10–48.5% [33-37]. The clin-
ical targeted next generation epilepsy panels include PDE-
ALDH7A1, PNPO and GLUT1 deficiencies and dystonia
panels include TH, GTPCH, GLUT1, SR and dopamine
transporter deficiencies. Expanding the genes in the tar-
geted next generation dystonia panels including SLC18A2
(VMAT2 deficiency), AADC gene (AADC deficiency),
QDPR (DHPR deficiency) and PTS (PTPS deficiency)
would preempt the necessity of CSF neurotransmitter me-
tabolite measurements. Targeted next generation sequen-
cing panels for dystonia and epilepsy would be the most
suitable investigation to apply as first line testing in pa-
tients with movement disorders and epilepsy rather than
using CSF neurotransmitter measurements. In patients
with high clinical suspicion of inherited neurotransmitter
disorders who have a negative molecular genetic investiga-
tion, CSF neurotransmitter measurements could be helpful
to guide symptomatic treatment.Conclusion
Our retrospective cohort study reports that the prevalence
of inherited neurotransmitter disorders is 4% in patients
with GDD, neonatal hypotonia, neonatal seizures, epilepsy
and movement disorders or newborn screening positive for
PKU who underwent CSF neurotransmitter measurements
for diagnostic work-up. These disorders include autosomal
dominant GTPCH deficiency, TH deficiency, PTPS defi-
ciency, DHPR deficiency, PDE-ALDH7A1 and PNPO defi-
ciency combining inherited monoamine and pyridoxine
metabolism disorders. In our cohort, 5.3% had one of the
treatable inherited metabolic disorders with favorable short-
term neurodevelopmental outcomes, highlighting the im-
portance of an early and specific diagnosis. Whole exome or
genome sequencing might shed light to unravel underlying
genetic defects of new inherited neurotransmitter disorders
in near future.
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